Morepen Laboratories Limited Share Price NSE India S.E.

MOREPENLAB

INE083A01026

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 12:05:08 17/07/2026 BST			5-day change	1st Jan Change
58.90 ^INR	-3.17%		-3.79%	+43.41%

07-01	Morepen Laboratories Limited Accelerates Manufacturing Expansion, Plans 1,000 KL Reactor Capacity	CI
07-01	Morepen Scales Up CDMO Program, Expects INR 2.25 Billion Supplies in Second Quarter of 2027	CI

Valuation: Morepen Laboratories Limited

Market Cap	18.52B 192M 168M 155M 143M 269M 275M 1.85B 729M 9.07B 722M 706M 31.23B	P/E 2024	22.4x	P/E 2025	21.8x
Enterprise Value	18.52B 192M 168M 155M 143M 269M 275M 1.85B 729M 9.07B 722M 706M 31.22B	EV / Sales 2024	1.27x	EV / Sales 2025	1.45x
Free-Float	57.31%	Yield 2024 *	-	Yield 2025	0.42%

* Estimated data More valuation ratios

Chart: Morepen Laboratories Limited

Dynamic Chart

Latest news : Morepen Laboratories Limited

07-01	Morepen Laboratories Limited Accelerates Manufacturing Expansion, Plans 1,000 KL Reactor Capacity	CI
07-01	Morepen Scales Up CDMO Program, Expects INR 2.25 Billion Supplies in Second Quarter of 2027	CI
05-26	Morepen Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
05-26	Morepen Laboratories Limited Recommends Final Dividend for the Year Ended 31 March, 2026	CI
05-26	Morepen Laboratories March-quarter consol net profit 157 million rupees	RE
05-19	Anubhav Suri agreed to acquire an additional 9% stake in Morepen Medipath Limited from Morepen Laboratories Limited.	CI
04-23	Morepen Laboratories Limited Approves Unsecured Term Loan Facility of INR 300 Million from Shinhan Bank	CI
04-17	Morepen Laboratories says USFDA clears Masulkhana API facility with nil Form 483 observations	RE
04-17	Morepen Laboratories Limited Receives USFDA Clearance for Masulkhana Facility Inspection with Zero Observations	CI
02-24	IT rout drags Indian markets; sector on track for worst month in 23 years on AI fears	RE
02-23	Morepen Laboratories gets order worth 8.25 bln rupees	RE
02-23	Morepen Laboratories Secures INR8.25 Billion CDMO Mandate; Shares Jump 13%	MT
02-23	Morepen Laboratories secures 8.25 billion rupees CDMO deal	RE

More news

Press Releases: Morepen Laboratories Limited

05-26	Morepen Laboratories : Audited Financial results for the quarter and financial year ended March 31, 2026 Unaudited financial results for the quarter and nine months ended December 31, 2025 Unaudited Financial results for the quarter and half year ended September 30, 2025 Unaudited Financial results for the quarter ended June 30, 2025	PU
04-17	Morepen Laboratories : Secures Fourth Consecutive USFDA Inspection with Zero Observations (NIL 483)	PU
02-23	Morepen Laboratories : Bags ₹825 Crore Global Deal; Expands Into High-Growth CDMO Segment.	PU
02-23	Morepen Laboratories : Bags ₹825 Crore Global Deal	PU
02-10	Morepen Laboratories : Q3'FY26 Presentation	PU

More press releases

Managers and Directors: Morepen Laboratories Limited

Manager	Title	Age	Since
Sanjay Suri CEO	Chief Executive Officer	57	30/06/2026
Sushil Suri CEO	Chief Executive Officer	62	31/01/1992
Ajay Kumar Sharma DFI	Director of Finance/CFO	59	02/04/2002

Director	Title	Age	Since
Sushil Suri CHM	Chairman	62	31/01/1992
Praveen Kumar Dutt BRD	Director/Board Member	57	12/08/2019
Savita BRD	Director/Board Member	-	21/06/2020

More insiders

Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.

Employees

1,814

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
17/07/26	₹58.90	-3.17%	7,705,689
16/07/26	₹60.83	-0.67%	4,567,550
15/07/26	₹61.24	-2.11%	10,976,573
14/07/26	₹62.56	+0.43%	10,096,836
13/07/26	₹62.29	+1.75%	15,187,668

Delayed Quote NSE India S.E.

More quotes

Income Statement and Estimates

More financial data

1 day	-3.17%
1 week	-3.79%
Current month	-0.37%
1 month	+15.42%
3 months	+40.57%
6 months	+56.19%
Current year	+43.41%

1 week	57.66	64.58
1 month	49.71	64.58
Current year	33.05	64.58
1 year	33.05	64.58
3 years	28.6	100.9
5 years	23.6	100.9
10 years	7.2	100.9

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MOREPEN LABORATORIES LIMITED	-3.17%	-3.79%	-	-	335M
ELI LILLY AND COMPANY	+0.85%	-0.80%	+52.79%	+161.33%	1,051B
JOHNSON & JOHNSON	+1.23%	-1.53%	+54.58%	+59.08%	609B
ABBVIE INC.	+0.04%	+2.58%	+34.47%	+86.33%	450B
ROCHE HOLDING AG	+0.78%	-0.71%	+29.28%	+24.10%	330B
NOVARTIS AG	+1.41%	+0.58%	+35.44%	+40.67%	284B
ASTRAZENECA PLC	-0.27%	-1.87%	+22.34%	+22.51%	263B
NOVO NORDISK A/S	-1.76%	+2.37%	-20.43%	-38.00%	223B
AMGEN INC.	-1.42%	+0.80%	+24.27%	+57.50%	198B
GILEAD SCIENCES, INC.	-1.48%	+3.43%	+24.08%	+71.67%	167B
Average	-0.38%	+0.54%	+28.54%	+53.91%	397.23B
Weighted average by Cap.	+0.37%	+0.02%	+37.51%	+79.63%

	2024	2025
Net sales	17.02B 177M 154M 143M 131M 248M 253M 1.7B 670M 8.34B 664M 649M 28.69B	18.12B 188M 164M 152M 140M 264M 269M 1.81B 713M 8.87B 706M 691M 30.54B
Net income	962M 9.99M 8.73M 8.05M 7.42M 13.99M 14.3M 96.24M 37.86M 471M 37.5M 36.68M 1.62B	1.18B 12.26M 10.71M 9.88M 9.11M 17.17M 17.55M 118M 46.46M 578M 46.02M 45.01M 1.99B
Net Debt	121M 1.25M 1.09M 1.01M 930K 1.75M 1.79M 12.06M 4.75M 59.04M 4.7M 4.6M 203M	-928K -9.64K -8.42K -7.77K -7.16K -13.5K -13.8K -92.88K -36.53K -454K -36.19K -35.4K -1.56M

Morepen Laboratories Limited Share Price NSE India S.E.

Stocks

MOREPENLAB

INE083A01026

Pharmaceuticals

Valuation: Morepen Laboratories Limited

Chart: Morepen Laboratories Limited

Latest news : Morepen Laboratories Limited

Press Releases: Morepen Laboratories Limited

Quotes and Performance

Course Extremes

Managers and Directors: Morepen Laboratories Limited

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates